{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.99","paramType":"Hazard Ratio (HR)","paramValue":"1.00","statisticalMethod":"Regression, Cox"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.84","paramType":"C-statistic","paramValue":"0.48","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.21","value":"-0.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Prediction efficacy is estimated using a hazard ratio (HR) and C-statistic (C-stat). Progression free survival is defined as the span of time from day 1 of therapy to date of disease recurrence (measured in months). Results are pooled with subjects from a pilot RDRC study for a total of 25 subjects analyzed.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects receive 2 18F-Fluorothymidine PET scans\n\n* Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)\n* Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)\n\nF-18 Fluorothymidine dose = 0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%).\n\nImaging technology: PET scan","id":"OG000","title":"FLT PET Scan"}],"paramType":"MEAN","populationDescription":"Participants who underwent both the pre-therapy and mid-therapy FLT PET scan","reportingStatus":"POSTED","timeFrame":"36 months","title":"Efficacy of Percent Change in FLT Flux (K-FLT) Between Scans 1 & 2 in Predicting Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage change in K-FLT"}